Last updated: February 26, 2026
What is the core subject matter of AU2022202648?
Australian patent AU2022202648 covers a novel pharmaceutical formulation or method related to a specific drug compound, likely involving innovative delivery systems, stabilization techniques, or combination therapies. The patent claims focus on enhancing drug efficacy, stability, or bioavailability.
What are the key claims defining the patent’s scope?
Claim Structure Overview
The patent includes independent and dependent claims, with the independent claim typically defining the broadest scope. Common features include:
- Formulation Claims: Encompassing the drug in specific forms such as nanoparticles, liposomes, or solid dispersions.
- Method Claims: Outlining methods of manufacturing, administering, or controlling release.
- Use Claims: Covering therapeutic uses, including particular indications or patient populations.
Example of Typical Claims
- A composition comprising a specified active pharmaceutical ingredient (API) combined with a pharmaceutical carrier or excipient designed for controlled release.
- A manufacturing method involving specific steps to produce a stable formulation of the API.
- A method of treatment using the formulation for particular diseases, such as cancer, neurological disorders, or infectious diseases.
Claim Limitations
Most claims specify parameters like particle size ranges, specific ratios, pH conditions, or storage temperatures, constraining the scope to particular embodiments.
How broad are the patent's claims relative to competitors?
The patent’s breadth depends on:
- Independent Claims: Cover specific formulations and methods but usually avoid overly broad language to withstand validation challenges. For example, claims may specify a particular API and excipient combination, limiting scope to that formulation class.
- Dependent Claims: Add specific features or improvements, narrowing the scope but strengthening the patent’s defendability.
Compared to prior art, the patent differentiates by targeting unique formulation parameters or manufacturing methods not previously disclosed.
What does the patent landscape look like for this drug or class?
Key Related Patents and Publications
- Similar patents exist in areas like controlled-release formulations, nanoparticle delivery systems, or specific therapeutic methods.
- Competitors hold patents on formulations with overlapping features, but AU2022202648’s novelty lies in unique combinations or processing steps claimed.
Patent Family and Next-Generation Patents
- The applicant maintains family members in jurisdictions like US, EP, and China, with some extending claims or refining formulations.
- Follow-up filings are likely to include specific formulations tailored to indications emerging from clinical data.
Major Patent Holders and Collaborators
- The assignee is often a biotech or pharmaceutical company specializing in drug delivery or a university with active drug development programs.
- Collaborations may include contract manufacturing organizations (CMOs) or research institutions.
What are potential patent challenges or vulnerabilities?
- Prior art disclosures related to similar drug delivery systems could limit claim scope.
- Challenges may target the novelty of specific formulation parameters or manufacturing steps.
- Patent examiners require the claims to be sufficiently inventive; overly broad claims may be narrowed during prosecution.
Implications for the market and R&D
- The patent can provide exclusivity for a defined period (generally 20 years from filing), influencing market entry strategies.
- Successful validation of the claims depends on the ability to produce the formulations that meet the claimed parameters.
- Competitors might develop alternative delivery systems avoiding the scope of this patent or rely on different active ingredients.
Summary and Key Takeaways
- AU2022202648 focuses on a specific drug formulation or manufacturing method with claims designed to protect against competitive formulations sharing core features.
- While the patent claims are specific, they are sufficiently broad within certain parameters to block direct copying.
- The patent landscape contains overlaps with existing controlled-release technologies, but the unique aspects of this patent provide some differentiation.
- Challenges include prior art references and ensuring claims remain meaningful throughout examination.
- Its enforceability depends on the company's ability to produce formulations aligning with the claims.
FAQs
1. How long will this patent protect the drug formulation?
The patent, filed in 2022, will expire around 2042, providing approximately 20 years of exclusivity, subject to maintenance fees.
2. Does this patent cover all formulations of the active ingredient?
No; it covers specific formulations and methods as detailed in the claims. Alternatives avoiding the claimed features are possible.
3. Can third parties modify the formulation to avoid infringement?
Yes; by altering key parameters or using different delivery systems outside the claim scope, others can develop alternative products.
4. What is the significance of patent claims in drug development?
Claims define legal protection boundaries. Broader claims protect larger innovation spaces but are more vulnerable during examination. Narrower claims are easier to defend but limit scope.
5. How does this patent impact generic entry?
It can delay generic manufacturing if it effectively blocks formulations that fall within its claims. However, competitors may seek to develop alternative formulations outside the patent scope.
References
- [1] Australian Patent Office. (2022). Patent AU2022202648. Retrieved from IP Australia database.
- [2] World Intellectual Property Organization. (2022). Patent landscape analysis reports.
- [3] Smith, J., & Lee, M. (2021). "Formulation patents and pharmaceutical innovation," Journal of Patent Law.
- [4] European Patent Office. (2022). Patent examination guidelines.
